Shares of Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) hit a new 52-week high on Monday . The stock traded as high as $52.83 and last traded at $52.83, with a volume of 0 shares trading hands. The stock had previously closed at $52.83.
Analyst Ratings Changes
Separately, HC Wainwright raised Basilea Pharmaceutica to a “strong-buy” rating in a report on Monday, September 23rd.
Read Our Latest Report on Basilea Pharmaceutica
Basilea Pharmaceutica Stock Performance
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Featured Articles
- Five stocks we like better than Basilea Pharmaceutica
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- Why Invest in High-Yield Dividend Stocks?
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- Industrial Products Stocks Investing
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
